Apatinib plus etoposide in pretreated patients with advanced triple-negative breast cancer: a phase...
Apatinib plus etoposide in pretreated patients with advanced triple-negative breast cancer: a phase II trial
About this item
Full title
Author / Creator
Cao, Mengru , Lu, Hailing , Yan, Shi , Pang, Hui , Sun, Lichun , Li, Chunhong , Chen, Xuesong , Liu, Wei , Hu, Jing , Huang, Jian , Xing, Ying , Zhang, Ningzhi , Chen, Yingqi , He, Ting , Zhao, Danni , Sun, Yuanyuan , Zhao, Lin , Liu, Xiaomeng and Cai, Li
Publisher
England: BioMed Central Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: BioMed Central Ltd
Subjects
More information
Scope and Contents
Contents
Treatment options for pretreated triple-negative breast cancer (TNBC) are limited. This study aimed to evaluate the efficacy and safety of apatinib, an antiangiogenic agent, in combination of etoposide for pretreated patients with advanced TNBC.
In this single-arm phase II trial, patients with advanced TNBC who failed to at least one line of che...
Alternative Titles
Full title
Apatinib plus etoposide in pretreated patients with advanced triple-negative breast cancer: a phase II trial
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_fb54b14704f0492e8e2b35bf4cc390f1
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_fb54b14704f0492e8e2b35bf4cc390f1
Other Identifiers
ISSN
1471-2407
E-ISSN
1471-2407
DOI
10.1186/s12885-023-10768-8
